Condition: CTCL · Sponsor: Prescient Therapeutics, Ltd.
This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.
This description comes directly from the study's public registry record.
Upaly Bahadure · +61 3 9692 7222 · upaly@ptxtherapeutics.com
David Wong · david.wong@ptxtherapeutics.com
Always discuss trial participation with your own doctor first.
| City of Hope Comprehensive Cancer Cente | Duarte, California, United States | Recruiting |
| University of California Irvine | Irvine, California, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Rochester Skin Lymphoma Medical Group. PLLC | Rochester, New York, United States | Recruiting |
| Virginia Commonwealth University Massey Comprehensive Cancer Cente | Richmond, Virginia, United States | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
| Epworth Healthcare | Melbourne, Victoria, Australia | Recruiting |
| Linear Clinical Research | Nedlands, Western Australia, Australia | Recruiting |
| CHU de Bordeaux - Hopital Saint André | Bordeaux, Bordeaux, France | Not Yet Recruiting |
| Hopital Lyon Sud | Lyon, Pierre-Benite, France | Not Yet Recruiting |
| Hopital Saint Louis | Paris, Île-de-France Region, France | Not Yet Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06854653